Weight-Loss Drug Shows Promise in Reducing Sleep Apnea

An experimental weight-loss drug significantly reduced episodes of interrupted breathing during sleep in two clinical studies involving people with obesity or excess weight.

The findings point to a potential new approach to sleep apnea, a common sleep disorder in which breathing repeatedly stops and starts during the night.

While snoring can be a sign of sleep apnea, the two are not interchangeable. The studies focused on breathing interruptions, rather than whether the drug could stop snoring alone.

The results suggest weight-loss medication could have a role in managing sleep apnea among people carrying excess weight. However, the available summary does not identify the drug or provide details on the size of the reduction, treatment duration or side effects.

The findings are promising, but they do not establish weight-loss injections as a general treatment for snoring. Further details are needed to assess how the experimental drug might fit into care for sleep apnea.